39 completed, 9 unknown, 4 terminated, 3 recruiting. 57 Phase 2, 12 Phase 3, 4 Phase 1.
Follow Rivaroxaban: new trials by email Literature Review of Rivaroxaban trials Research Report on Rivaroxaban
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| A Pilot Trial Comparing Full Dose Rivaroxaban to Prophylactic Dose Rivaroxaban in Patients With Superficial Vein Thrombosis in the Leg Full dose rivaroxaban, Low dose rivaroxaban, Placebo - SVT, Thrombosis | Phase 2 / Phase 3 | Recruiting | Ottawa Hospital Research Institute | 50 | 2025-08-06 | 2025-08-11 |
| VTE Prevention With Rivaroxaban in Genitourinary Cancer Patients Receiving Systemic Therapy Rivaroxaban 10 MG, Placebo control - Venous Thromboembolism, Urologic Cancer | Phase 2 / Phase 3 | Recruiting | Ottawa Hospital Research Institute | 120 | 2024-11-04 | 2026-11-12 |
| HIP Fracture Oral thromboPROphylaxis (Hip PRO Pilot) Rivaroxaban 10mg, acetylsalicylic acid (ASA) 81mg Oral Tablet - Hip Fractures | Phase 2 | Recruiting | University of Calgary | 250 | 2024-05-21 | 2026-10-09 |
| A Study to Evaluate the Efficacy and Safety of SHR-2004 Injection in Preventing Postoperative Venous Thromboembolism in Patients Undergoing Ovarian Cancer Surgery SHR-2004, Enoxaparin Sodium Injection; Rivaroxaban Tablets - Preventing Postoperative Venous Thromboembolism in Patients Undergoing Ovarian Cancer Surgery | Phase 2 | Completed | Beijing Suncadia Pharmaceuticals Co., Ltd | 225 | 2024-02-16 | 2025-07-22 |
| Anticoagulation Using Rivaroxaban on Top of Aspirin in Intracranial Atherosclerotic Stenosis Rivaroxaban, Clopidogrel, Aspirin - Ischemic Stroke, Intracranial Atherosclerosis | Phase 2 / Phase 3 | Unknown | The First Affiliated Hospital with Nanjing Medical University | 1180 | 2023-12-30 | 2023-12-21 |
| Comparison of the Effect of Medication Therapy in Alleviating Migraine With Patent Foramen Ovale Aspirin 300mg, Metoprolol 25mg, Clopidogrel 75mg - Patent Foramen Ovale, Migraine | Phase 2 | Completed | Chinese Academy of Medical Sciences, Fuwai Hospital | 1000 | 2022-10-15 | 2026-04-22 |
| The Safety of Non-vitamin K Oral Anticoagulants Compared to Warfarin Early After Cardiac Surgery Non-vitamin K oral anticoagulants (NOACs), Warfarin - Atrial Fibrillation | Phase 2 | Unknown | St. Paul's Hospital, Canada | 100 | 2022-10-12 | 2024-04-17 |
| DOAC Versus VKA After Cardiac Surgery Warfarin, Dabigatran, Rivaroxaban - Anticoagulant-induced Bleeding | Phase 2 | Withdrawn | Laval University | 2022-03-09 | 2023-03-13 | |
| Efficacy and Safety of Apixaban in COVID-19 Coagulopathy Patients With Respiratory Severity Under Critical Care Apixaban, Rivaroxaban - COVID-19 | Phase 2 | Unknown | Scotmann Pharmaceuticals | 40 | 2022-03-01 | 2022-03-10 |
| Antithrombotic Therapy in Acute Coronary Syndromes and Coronary Artery Ectasia Rivaroxaban 15 MG, Acetylsalicylic acid 100mg, Clopidogrel 75 Mg Oral Tablet - Acute Coronary Syndrome, Coronary Artery Ectasia | Phase 2 | Unknown | Instituto Nacional de Cardiologia Ignacio Chavez | 60 | 2021-09-01 | 2022-02-10 |
| RIvaroxaban for Stroke Patients With AntiPhospholipid Syndrome Rivaroxaban, Warfarin - Antiphospholipid Syndrome, Systemic Lupus Erythematosus | Phase 2 | Completed | University College, London | 43 | 2021-07-09 | 2026-05-22 |
| Rivaroxaban in Type 2 Myocardial Infarctions Rivaroxaban 2.5 MG [Xarelto], Placebo - Type II Myocardial Infarction | Phase 2 / Phase 3 | Completed | University of Alberta | 8 | 2021-04-05 | 2023-03-27 |
| Safety and Tolerability of Abelacimab (MAA868) vs. Rivaroxaban in Patients With Atrial Fibrillation Abelacimab, Rivaroxaban - Atrial Fibrillation (AF), Stroke | Phase 2 | Active not recruiting | Anthos Therapeutics, Inc. | 1287 | 2021-02-02 | 2025-11-06 |
| Rivaroxaban Plus Aspirin to Manage Recurrent Venous Thromboembolic Events Rivaroxaban 20 MG [Xarelto], Aspirin 300mg, Acenocoumarol Oral Tablet - Venous Thromboembolism, Anticoagulant-induced Bleeding | Phase 2 / Phase 3 | Completed | Instituto Mexicano del Seguro Social | 58 | 2021-01-03 | 2022-08-25 |
| Factor Xa Inhibitor Versus Standard of Care Heparin in Hospitalized Patients With COVID-19 (XACT) Enoxaparin, Rivaroxaban - Covid19 | Phase 2 | Completed | St. David's HealthCare | 150 | 2020-12-01 | 2021-06-30 |
| Effect of Anticoagulation Therapy on Clinical Outcomes in COVID-19 Rivaroxaban, Standard Of Care (SOC) - COVID-19 | Phase 2 | Terminated | Charite University, Berlin, Germany | 111 | 2020-11-30 | 2022-01-12 |
| A Trial to Evaluate Safety and Efficacy of Rivaroxaban (COVID-19) Rivaroxaban, Placebo - COVID-19 | Phase 2 | Terminated | Gates Medical Research Institute | 497 | 2020-09-02 | 2021-10-22 |
| Rivaroxaban Plus ASA in Embolic Stroke of Undetermined Source(AREST-ESUS) Rivaroxaban 2.5 Mg Oral Tablet, Rivaroxaban placebo tablets - Stroke, Prevention | Phase 2 / Phase 3 | Completed | Mazandaran University of Medical Sciences | 42 | 2020-08-22 | 2023-10-19 |
| Austrian CoronaVirus Adaptive Clinical Trial (COVID-19) Chloroquine or Hydroxychloroquine, Lopinavir/Ritonavir, Best standard of care - COVID-19 | Phase 2 / Phase 3 | Unknown | Medical University of Vienna | 500 | 2020-04-16 | 2021-03-02 |
| Study of Rivaroxaban for CeREbral Venous Thrombosis Rivaroxaban, Standard of care - Cerebral Venous Thrombosis | Phase 2 | Completed | University of British Columbia | 55 | 2019-03-12 | 2022-12-14 |
Showing 20 of 57. Sign in to see all of them.
Venous Thromboembolism (12) · Atrial Fibrillation (6) · Stroke (6) · COVID-19 (5) · Thrombosis (5) · Venous Thrombosis (5) · Ischemic Stroke (4) · Pulmonary Embolism (4) · Acute Coronary Syndrome (3) · Hemorrhage (3) · Cardiovascular Diseases (2) · Coronavirus Infections (2) · Embolism (2) · Embolism and Thrombosis (2) · Heart Valve Diseases (2)
Bayer (14) · Ottawa Hospital Research Institute (3) · Asan Medical Center (2) · Insel Gruppe AG, University Hospital Bern (2) · Portola Pharmaceuticals (2) · Anthos Therapeutics, Inc. (1) · Assistance Publique - Hôpitaux de Paris (1) · Beijing Suncadia Pharmaceuticals Co., Ltd (1) · Capital Medical University (1) · Charite University, Berlin, Germany (1) · Chinese Academy of Medical Sciences, Fuwai Hospital (1) · First Affiliated Hospital Xi'an Jiaotong University (1) · Gates Medical Research Institute (1) · Hanyang University Seoul Hospital (1) · Hospital Geral Roberto Santos (1)
Canada (15) · United States (12) · Netherlands (11) · Austria (10) · Israel (9) · Italy (9) · Poland (9) · France (8) · Germany (8) · Belgium (7) · Brazil (7) · Australia (6) · Hungary (6) · Spain (6) · Sweden (6)
Alexandra Arias Mendoza, MD (1) · Andre Duraes, PhD (1) · Athena Sharifi-Razvi (1) · Bernd Jilma, MD (1) · Byung-Woo Yoon, PhD (1) · Choonghyoek Choi (1) · Diego Araiza Garaygordobil, MD, MSc (1) · Edward Chafizadeh, MD (1) · Esteban Gandara, MD (1) · Eung-Gyu Kim, PhD (1)
PMID 31420317, PMID 31535314, PMID 35244208, PMID 15189396, PMID 15842354, PMID 18094721, PMID 18621928, PMID 19539361, PMID 20637084, PMID 21570509, PMID 22409262, PMID 23903204, PMID 25346499, PMID 25925992, PMID 26458895, PMID 26986753, PMID 26995378, PMID 27075710, PMID 28325638, PMID 28892526, PMID 30293126, PMID 30903459, PMID 31141104, PMID 31837559, PMID 32092140, PMID 32674675, PMID 33045224, PMID 33150497, PMID 33196155, PMID 33502773, PMID 33660875, PMID 34172290, PMID 34473343, PMID 34582035, PMID 35141170, PMID 35904750, PMID 35935856, PMID 36220325, PMID 36413425, PMID 37227726, PMID 37591523, PMID 37675613, PMID 38109984, PMID 39615618, PMID 39842011, PMID 40037214, PMID 40269760, PMID 40546068, PMID 41637102, PMID 42213637
2014 (3), 2004 (1), 2008 (1), U01HL117659 (1)